Heme Oxygenase 1 Determines Atherosclerotic Lesion Progression into a Vulnerable Plaque
Overview
Authors
Affiliations
Background: The molecular regulation for the transition from stable to vulnerable plaque remains to be elucidated. Heme oxygenase 1 (HO-1) and its metabolites have been implicated in the cytoprotective defense against oxidative injury in atherogenesis. In this study, we sought to assess the role of HO-1 in the progression toward plaque instability in carotid artery disease in patients and in a murine model of vulnerable plaque development.
Methods And Results: Atherectomy biopsy from 112 patients with clinical carotid artery disease was collected and stratified according to characteristics of plaque vulnerability. HO-1 expression correlated closely with features of vulnerable human atheromatous plaque (P<0.005), including macrophage and lipid accumulation, and was inversely correlated with intraplaque vascular smooth muscle cells and collagen deposition. HO-1 expression levels correlated with the plaque destabilizing factors matrix metalloproteinase-9, interleukin-8, and interleukin-6. Likewise, in a vulnerable plaque model using apolipoprotein E(-/-) mice, HO-1 expression was upregulated in vulnerable versus stable lesions. HO-1 induction by cobalt protoporphyrin impeded lesion progression into vulnerable plaques, indicated by a reduction in necrotic core size and intraplaque lipid accumulation, whereas cap thickness and vascular smooth muscle cells were increased. In contrast, inhibition of HO-1 by zinc protoporphyrin augmented plaque vulnerability. Plaque stabilizing was prominent after adenoviral transduction of HO-1 compared with sham virus-treated animals, providing proof that the observed effects on plaque vulnerability were HO-1 specific.
Conclusions: Here we demonstrate in a well-defined patient group and a murine vulnerable plaque model that HO-1 induction reverses plaque progression from a vulnerable plaque to a more stable phenotype as part of a compensatory atheroprotective response.
Hwang H, Kim J, Yun S, Park M, Song E, Jang S Endocrinol Metab (Seoul). 2023; 38(6):760-769.
PMID: 37915121 PMC: 10765001. DOI: 10.3803/EnM.2023.1774.
Chen W, Nadel J, Tumanov S, Stocker R Int J Mol Sci. 2023; 24(13).
PMID: 37445903 PMC: 10341695. DOI: 10.3390/ijms241310727.
Underlying mechanisms of thrombus formation/growth in atherothrombosis and deep vein thrombosis.
Yamashita A, Asada Y Pathol Int. 2023; 73(2):65-80.
PMID: 36598039 PMC: 11551813. DOI: 10.1111/pin.13305.
Rangarajan S, Orujyan D, Rangchaikul P, Radwan M Biomedicines. 2022; 10(11).
PMID: 36359349 PMC: 9687471. DOI: 10.3390/biomedicines10112829.
Jiang Z, Zhang M, Liu K, Xue Y, Li X, Dong C Fish Physiol Biochem. 2022; 48(1):117-131.
PMID: 35006528 DOI: 10.1007/s10695-021-01041-5.